high-throughput genotyping method sequenom massarray (Sequenom)
90
Structured Review
Sequenom
high-throughput genotyping method sequenom massarray
High Throughput Genotyping Method Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/high-throughput+genotyping+method+sequenom+massarray/sequenom+massarray/10__1016_slash_j__ygyno__2009__12__013-7033-5-8
Average 90 stars, based on 1 article reviews
High Throughput Genotyping Method Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/high-throughput+genotyping+method+sequenom+massarray/sequenom+massarray/10__1016_slash_j__ygyno__2009__12__013-7033-5-8
Average 90 stars, based on 1 article reviews
high-throughput genotyping method sequenom massarray - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Abstracts Presented for the 41st Annual Meeting of the Society of Gynecologic Oncologists Article Snippet: Abstracts Presented for the 41st Annual Meeting of the Society of Gynecologic Oncologistss Presented for the 41st Annual Meeting of the Society of Gynecologic Oncologists Opening Plenary Session 1 Sunday, March, 14, 2010, 10:15AM-11:46AM General Session Ballroom 3rd Floor, Convention Center, (Moscone West Convention Center) Moderator, Abstracts 1−5: Robert Coleman, MD, The University of Texas, MD Anderson Cancer Center, Houston, TX 1 GOG 175: A Randomized phase III trial of IV carboplatin (AUC 6) and paclitaxel 175 mg/m Q 21 days × 3 courses plus low-dose paclitaxel 40 mg/m/wk versus IV carboplatin (AUC 6) and paclitaxel 175 mg/m Q 21 days × 3 courses plus observation in patients with early-stage ovarian carcinoma R. Mannel , M. Brady , E. Kohn , P. Hanjani , M. Hiura , R. Lee , K. De Geest , D. Cohn , B. Monk , H. Michael 10 1 University of Oklahoma, Oklahoma City, OK, 2 Roswell Park Cancer Institute, Buffalo, NY, 3 National Cancer Institute, Bethesda, MD, 4 Abington Memorial Hospital Rosenfeld Cancer Center, Abington, PA, 5 Shikoku Cancer Center, Matsuyama, Japan, 6 Southwest Gynecologic Oncology Associates, Inc., Lakewood, WA, 7 University of Iowa, Iowa City, IA, 8 The Ohio State University, Columbus, OH, 9 University of California Irvine, Orange, CA, 10 Indiana University School of Medicine, Indianapolis, IN Objective: The objective of this study was to compare progressionfree survival, overall survival, and toxicity in patients with completely resected stage IA (grade 3 or clear cell), IC, or II epithelial ovarian cancer treated with intravenous carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks.. Methods: Eligibility was restricted to patients with high-risk earlystage ovarian cancer undergoing definitive surgical staging and complete resection of disease entered within six weeks of staging surgery.. Patients with GOG performance status grade 4, borderline tumors, or evidence of other invasive malignancies within the past five years were not eligible. |